Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward
The expert from SUNY Downstate Medical Center highlighted areas in which he believes treatment for renal cell carcinoma will advance.
In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, spoke about where he believes renal cell carcinoma treatment will advance in the coming years.
Transcription:
Tivozanib [Fotivda] is a [tyrosine kinase inhibitor]. There are a lot of different drugs that are approved for renal cell carcinoma. One of the future [prospects] is obviously for the PD-1 class to move into renal cell carcinoma more and more. Combinations with PD-1 [inhibitors] is one area. Hopefully, if tivozanib is approved, then I think other sponsors and perhaps the sponsor of the drug itself will look into combining it with other agents including [PD-1 inhibitors]. So that’s one likely future avenue for the treatment of renal cell carcinoma.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
